<DOC>
	<DOCNO>NCT01915524</DOCNO>
	<brief_summary>The purpose study determine whether new RNActive derive lung cancer vaccine CV9202 combination local radiation therapy safe , tolerable immunogenic consolidation maintenance treatment stage IV non small cell lung cancer ( NSCLC ) first-line chemotherapy therapy EGFR tyrosine kinase inhibitor .</brief_summary>
	<brief_title>Trial RNActive®-Derived Cancer Vaccine Local Radiation Stage IV Non Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>The Phase Ib study first clinical study new lung cancer vaccine CV9202 . The vaccine compose 6 RNActive compounts , encode different antigen overexpressed NSCLC compare healthy tissue . In order enhance immunogenic effect cancer vaccine , study treatment include local radiation ( 4 x 5 Gy ) , well-established palliative radiation regimen safely apply metastatic lesion lung , bone , soft tissue , well tolerate . Patients enrol 3 stratum base histologic molecular subtypes follow : Stratum 1 : Patients metastatic stage IV NSCLC non-squamous histology , without activate epidermal growth factor receptor ( EGFR ) mutation , achieve partial response ( PR ) stable disease ( SD ) least 4 cycle platinum- pemetrexed-based first-line chemotherapy , indication maintenance therapy pemetrexed . Stratum 2 : Patients stage IV NSCLC squamous cell histology , achieve PR SD least 4 cycle platinum-based non-platinum compound first-line chemotherapy . Stratum 3 : Patients stage IV NSCLC non-squamous histology , harbor activate EGFR mutation , achieve PR 6 month SD 3 - 6 month treatment EGFR TKI . In patient , vaccine administer progression need start subsequent systemic second-line treatment , occurrence unacceptable toxicity require treatment discontinuation , whichever come first .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Key 1 . Patients &gt; = 18 year age histologically cytologicallyconfirmed stage IV NSCLC , confirm EGFR mutation status case nonsquamous cell histology Stratum 1 : Nonsquamous NSCLC without activate EGFR mutation Stratum 2 : Squamous NSCLC Stratum 3 : Nonsquamous NSCLC harbor activate EGFR mutation 2 . PR SD accord RECIST Version 1.1 firstline therapy consist : Stratum 1 : PR SD cisplatin carboplatin pemetrexed treatment ( least 4 cycle ) Stratum 2 : PR SD cisplatin carboplatin nonplatinum compound treatment ( least 4 cycle ) Stratum 3 : PR 6 month SD least 3 6 month gefitinib erlotinib treatment 3 . For patient stratum 1 , maintenance therapy pemetrexed indicated investigator 's opinion 4 . Presence least one tumor lesion eligible radiation 4 x 5 GY , least one additional measurable tumor lesion accord RECIST Version 1.1 . Tumor lesion eligible radiation : Bone metastases Lymph node paraclavicular , axillary cervical region Skin subcutaneous metastasis For patient strata 1 2 : Thoracic lesion ( centrally locate lung tumor , lymph node lung hilus mediastinum ) 5 . Performance Status : Eastern Cooperative Oncology Group ( ECOG ) 0 1 Key 1 . Previous active immunotherapy NSCLC ( include vaccination , therapy antiCTLA4 antibody ) 2 . Estimated life expectancy ≤ 3 month 3 . Need immunosuppressive treatment include daily systemic steroid dose ≥ 10 mg prednisone equivalent per day 4 . Active skin disease ( e.g . atopic dermatitis ) area vaccine injection ( upper arm thigh ) allow intradermal injection area healthy skin 5 . Concurrent plan major surgery 6 . Prior splenectomy prior allogeneic bone marrow transplantation 7 . History pneumonitis 8 . Documented history active autoimmune disorder exception vitiligo , diabetes mellitus type 1 autoimmune thyroiditis require hormone replacement 9 . Primary secondary immune deficiency 10 . Allergies component study drug include allergy protamine hydrochloride ( e.g . allergy protaminecontaining insulin ) fish allergy 11 . Seropositive HIV , HBV , HCV infection require antiinfection therapy 12 . For patient stratum 3 : persisting &gt; = grade 3 skin rash time enrollment 13 . Known brain metastasis exception stable metastasis treat stereotactic radiation surgery ) **Local German Amendment : 13 . Brain metastasis ( symptomatic asymptomatic ) leptomeningeal involvement 14 . Uncontrolled medical condition consider high risk treatment investigational drug ( e.g . unstable diabetes mellitus , venacavasyndrome , uncontrolled pleural effusion , pericardial effusion , symptomatic congestive heart failure ( New York Heart Association 3 4 ) , unstable angina pectoris/myocardial infarction within previous 6 month , significant cardiac arrhythmia , history stroke transient ischemic attack within previous 6 month , severe hypertension accord WHO criterion , uncontrolled systolic blood pressure ≥ 180 mmHg time enrollment 15 . For patient plan undergo radiation thoracic lesion : inadequate lung function dependent intend tumor volume location irradiate ( assessed radio oncologist ) 16 . History encephalitis multiple sclerosis 17 . Active inflammatory condition inflammatory bowel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>